Albireo Pharma, Inc.

Bylvay global net product revenue was $7.5 million in Q3 2022, compared with $1.1 million in Q3 2021. U.S. revenue was $4.1 million and international revenue was $3.4 million. Royalty revenue was $2.3 million versus $2.6 million a year ago. Cost of product revenue was $0.6 million versus $0.4 million. R&D expense was $23.3 million, up from $21.1 million, and SG&A was $20.6 million, up from $17.6 million. Net loss was $37.8 million, or $1.92 per share, versus net income of $57.1 million, or $2.90 per share, in Q3 2021; the prior-year profit reflected the sale of the priority review voucher. Bylvay patient count was 270, up 25 from the prior quarter, with 126 reimbursed patients and 77 pending reimbursement. Management left 2022 Bylvay revenue guidance at $24 million. Cash, cash equivalents and restricted cash totaled $272.5 million at September 30, 2022, and the company said this should fund the business beyond the BOLD study top-line readout in 2024.

Ron Cooper framed the quarter as a validation of Bylvay’s “best-in-class” profile, emphasizing that the drug is already approved in PFIC and now has supportive Phase 3 data in Alagille syndrome plus new evidence suggesting native liver survival benefit in PFIC. He repeatedly pointed to Bylvay’s once-daily dosing, low therapeutic dose, ease of administration, and low diarrhea rates as differentiators versus other IBAT inhibitors. His tone was upbeat and expansion-oriented, stressing future launches in Alagille syndrome and biliary atresia and reiterating the aspiration of making Bylvay a billion-dollar drug in the second half of the decade.

Simon Harford focused on the quarter’s financial scaling and the balance sheet. He cited $7.5 million of Bylvay revenue, $2.3 million of royalty revenue, $23.3 million of R&D, $20.6 million of SG&A, and a $37.8 million net loss, and explained that the Sagard royalty monetization brought in $111.6 million upfront but is treated as debt for reporting purposes. He said cash, cash equivalents and restricted cash of $272.5 million should be enough to carry the company beyond the BOLD biliary atresia top-line readout in 2024, while noting Q4 international sales could be affected by the end of the 12-month repricing period in Germany.

Analysts pressed on whether reimbursed patient counts can be used to forecast revenue, and management said they are only a directional indicator because patient size and age create meaningful revenue variability, though the trend is upward and becoming more stable over time. Questions also focused on the PFIC native liver survival data and whether it could support label changes; Ron Cooper said the company will continue generating datasets and expects discussions with regulators as the data mature. On biliary atresia, management said Bylvay could potentially delay or even prevent transplant, and on Europe they said existing payer relationships and reimbursement experience should help the Alagille launch go smoothly.